مجله دانشکده پزشکی اصفهان
پیاپی 659 (هفته سوم فروردین 1401)

In patients undergoing surgery, hemodynamic disorders are common. Therefore, we decided to compare the effects of fentanyl and dexmedetomidine on hemodynamic changes in patients undergoing Stereotactic surgery. 

In this double blinded clinical trial, 68 candidates for Stereotactic Surgery in Alzahra Hospital in 2017 enrolled in the study. Patients were randomly divided into two groups; the first group was given bolus of 2 μg / kg fentanyl, and in the second group a loading dose of 1 μgr / kg / 10 min, followed by maintenance dose of: 0.5 μg / kg / h of dexmedetomidine was admininstered intravenously. The Dexmedetomidine was infused immediately following anesthesia induction. The hemodynamic variables in the two groups were evaluated.

There was no significant difference between the two groups based on systolic and diastolic blood pressure and oxygen saturation at different times. The heart rate in the dexmedetomidine group at 30, 60 and 90 minutes was significantly lower than fentanyl. On the other hand, there was no significant difference between the two groups with regards to pH, Pco2 and HCO3 before and after operation and recovery time.

Both dexmedetomidine and fentanyl are two effective drugs for controlling hemodynamics parameters in patients undergoing stereotactic surgery, but dexmedetomidine drug reduces heart rate significantly compared with fentanyl.

Anemia is a condition in which the concentration of hemoglobin (Hb) or red blood cell count (RBC) is lower than normal and is not sufficient to meet the physiological needs of the individual. Several genetic polymorphisms associated with iron status have been identified. The aim of this study was to investigate the relationship between rs4820268G > A polymorphism and iron deficiency anemia in Sanandaj. 

In this case-control study, 120 individuals including 40 patients with iron deficiency anemia (based on the results of ferritin test; hemoglobin, CBC and MCV) alongside 80 healthy individuals were studied. After DNA extraction, genotypes of individuals were examined by RFLP-PCR technique and the effect of HPY99I enzyme.

The frequency of AA, AG and GG genotypes among patients were (25) 25, (4) 10 and (26) 65% and in healthy group (57) 71.25, (17) 21.25 and (6) 5/ 7%, respectively. The odds ratio (OR) of the genotype, GG, is 22 times higher than that of AA. Also, the Hardy-Weinberg test showed a balanced population in this analysis.

The results showed a significant relationship between GG and AA genotypes with disease and health, respectively (P < 0.001). In other words, individual with GG genotype had lower Hb, MCV and Ferritin than people with AA and AG genotypes.

Chronic myeloid leukemia is a type of myeloproliferative malignancy that is associated with translocation between chromosomes 9 and 22 and accounts for approximately 15% of all leukemia. SNHGs are a subset of long non-coding RNAs that are considered to host small nuclear RNAs. SNHG5 is a regulatory factor in gene expression in various cancers, including chronic myeloid leukemia. The aim of this study was to evaluate and compare the expression level of SNHG5 in the peripheral blood sample of patients with chronic myeloid leukemia compared to normal individuals and then to evaluate SNHG5 as a potential biomarker in these patients. 

This study was conducted with a case-control design. First, the accuracy of chronic myeloid leukemia was confirmed using karyotype, molecular and cellular methods. After RNA extraction from white blood cells and cDNA synthesis, gene expression was measured using Real Time PCR. Finally, the data were statistically analyzed.

Findings of this study showed that the expression level of SNHG5 in patients with chronic myeloid leukemia significantly increased compared to normal individuals (P < 0.001). Increased expression may indicate the potential role of this molecule in the development and progression of this cancer.

The present study demonstrates the effective role of SNHG5 in the progression of chronic myeloid leukemia and can be investigated as a biomarker and potential therapeutic target in future studies